ProXara Biotechnology Limited is a recently-formed biotechnology company whose mission is to be a world leader in the development of novel therapeutically-relevant cell-based and in-vitro high throughput screens for drug discovery in the oncology field.

The Company was founded by Professor Jeremy Tavaré in the Department of Biochemistry at the University of Bristol and was incorporated in March 2001. The company is supported by an experienced and entrepeneurial management team.

ProXara has received funding from the Sulis Seedcorn Fund Partnership Limited, Catalyst BioMedica, The Wellcome Trust and private sources. Its premises are currently in the School of Medical Sciences in the University of Bristol.

ProXara have established a portfolio of novel cell-based and in-vitro assays against important intra-cellular targets in cancer (primarily breast and prostate) for screening against both internal and customer compound collections. Breast and prostate cancers are the most prevalent malignancies in women and men respectively, and the second highest cause of cancer deaths. The company's technologies will allow the discovery of drugs with a completely novel mode of action against relevant and validated targets.

ProXara is currently undertaking optimisation of a series of proprietary drug-like molecules which could provide a novel route for the treatment of cancer.